Advanced Search
Search
  
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire

Other News Releases in Health Care & Hospitals

Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill

Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation

FRC: Senate Votes to Proceed with Abortion Funding Debacle

Other News Releases in Patent Law

Document Security Systems Announces Ruling in Patent Validity Hearing by Austrian Patent Office

Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East

Federal Court Supports TransUnion and VantageScore(R)

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

See more news releases in: Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals

 

Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies

MENLO PARK, Calif., May 4 /PRNewswire/ -- Acclarent, Inc., the pioneer of Balloon Sinuplasty(TM) technologies for use in the treatment of chronic sinusitis, announced today that the U.S. Patent and Trademark Office awarded U.S. Patent Number 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat," to the company. This patent and Acclarent's earlier 7,462,175 patent are directed to methods for treating a paranasal sinus ostium, such as the maxillary sinus ostium, either through the nostril or other routes. The patented methods include advancing a balloon through a guide and using the balloon to dilate a paranasal sinus ostium. "In addition to securing protection for this early innovation, we believe this key patent underscores Acclarent's strength in intellectual property and deepens the cornerstone of our patent portfolio for Balloon Sinuplasty(TM)," states Acclarent CEO, Bill Facteau.

With this latest patent, Acclarent now owns or has exclusive rights to nine issued U.S. patents and over 120 pending U.S. and foreign patent applications.

"Acclarent's innovative Balloon Sinuplasty(TM) technology has been used by physicians throughout the world to improve the quality of life for thousands of patients suffering from chronic rhinosinusitis," said Facteau. "Acclarent is committed to continuing its leadership in innovation. This patent protects an important portion of Acclarent's technology assets and further differentiates Acclarent as a leader in the ENT community. The validation by the USPTO of our invention is a significant step in continuing to provide physicians and patients with access to safe and effective minimally invasive technology."

ABOUT ACCLARENT, INC.

Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally.

SOURCE Acclarent, Inc.